

What is claimed is:

1. A method of treating a neurodegenerative disease or disorder comprising administering an effective amount of
5 a compound that replaces or enhances the function of SMN to alleviate or reduce a phenotype of cells with low SMN protein levels.
2. The method of claim 1 wherein the compound
10 comprises Formula I, II or III.
3. The method of claim 1 wherein the compound comprises Compound 1, Compound 2, Compound 3, Compound 4,
Compound 5, Compound 6, Compound 7, Compound 8, Compound 9,
15 Compound 10, Compound 11, Compound 12, Compound 13, Compound 14, Compound 15, Compound 16, Compound 17, Compound 18, Compound 19, Compound 20, Compound 21, Compound 22, Compound 23, Compound 24, Compound 25, Compound 26, Compound 27, Compound 28, Compound 29,
20 Compound 30, Compound 31, Compound 32, Compound 33, Compound 34, Compound 35, Compound 36, Compound 37, Compound 38, or Compound 39.
4. A method of identifying a psychopharmacological
25 agent comprising contacting a test cell, which has low SMN protein levels, with a test agent and detecting an ability of said agent to alleviate or reduce a phenotype of said cells, wherein the ability of said agent to alleviate or reduce a phenotype said cells is indicative of said agent
30 being a psychopharmacological agent.
5. A method of treating a psychiatric disease or disorder comprising administering an effective amount of a

psychopharmacological agent identified by the method of claim 4.

6. A method of treating a psychiatric disease or
5 disorder comprising administering an effective amount of Compound 38, Compound 39, or Compound 40.

7. A psychopharmacological composition comprising a psychopharmacological agent identified by the method of
10 claim 4 and a pharmaceutically acceptable carrier.

8. A kit for identifying a psychopharmacological agent comprising a test cell, which has low SMN protein levels, and a positive or negative standard.